MyFinsight
Home
Blog
About
Maturities of marketable
securities
$29,600K
Net cash used in
investing activities
$17,886K
Canceled cashflow
$11,714K
Net increase in
cash, cash...
-$201,982K
Canceled cashflow
$17,886K
Proceeds from stock
option exercises, net...
$5,223K
Issuance costs
associated with royalty...
-$3,010K
Other liabilities
$47,788K
Stock-based compensation
$44,072K
Noncash interest
expense on deferred...
$41,345K
Accrued compensation
and benefits
$11,721K
Accrued research and
development liabilities
$10,038K
Net loss from equity
method investments
-$6,435K
Amortization of debt discount
and issuance costs
$1,926K
Noncash lease expense
$1,628K
Other noncash
adjustments, net
-$1,196K
Depreciation and
amortization
$1,053K
Purchases of marketable
securities
$11,271K
Purchases of property and
equipment
$443K
Net cash provided by
financing activities
-$148,767K
Net cash used in
operating activities
-$71,101K
Canceled cashflow
$8,233K
Canceled cashflow
$167,202K
Repurchase of common stock
$127,503K
Repayments of deferred
royalty obligations
$21,789K
Net loss
-$155,891K
Repurchase of rsu shares to
satisfy tax withholding
$4,267K
Issuance costs and
discounts associated with...
$431K
Accounts receivable, net
$49,258K
Inventories
$21,113K
Change in fair value of
the embedded...
$3,572K
Deferred revenue
-$1,921K
Accounts payable
-$1,856K
Operating lease
liabilities
-$1,822K
Other assets
$1,488K
Prepaid expenses and
other current assets
$1,382K
Back
Back
Cash Flow
BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. (BBIO)
source: myfinsight.com